1018 ISS

Drug Profile

1018 ISS

Alternative Names: First generation 1018 ISS - Dynavax; ISS 1018; ISS DNA; ISS1; ISS2

Latest Information Update: 16 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dynavax Technologies
  • Developer Dana-Farber Cancer Institute; Dynavax Technologies
  • Class DNA; Oligonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Allergic asthma
  • Discontinued Colorectal cancer; Human papillomavirus infections; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Apr 2008 Discontinued - Preclinical for Human papillomavirus infections in USA (unspecified route)
  • 08 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the adverse events section
  • 30 Nov 2006 Phase-I clinical trials in Colorectal cancer (combination therapy, second-line therapy or greater) in USA (SC) (NCT00403052)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top